P3 results & share performance18 Dec 2021 09:49
I should start by saying I'm a long term holder (first bought at 19p) and of the opinion that SNG will eventually go to 500p or higher.
However, it's worth noting that the on-the -day gains following the announcement of P3 results is unlikely to replicate the 500% rise we saw after P2. Why? Because the likelihood of good P2 results is much lower than good P3. Only 15% of respiratory drugs going into P2 get to market, compared to 80+% going into P3.
Indeed, the average share price gain for biotech companies on announcement of positive P3 results is 23%.
Obviously since SNG only has one drug, its market cap is likely to be much more significantly affected by positive P3 results than a company with a whole roster of drugs already on the market.
But people on here are talking about a 300% rise on the day P3 results come out and that seems just a tad overbullish to me but delighted to hear other views.
By the way, in terms of risk, the average decline following bad a P3 readout is over 70%! But let me quickly add I'm certainly not expecting that at all and think P3 will as good as we all hope.
300% gain over the next year very possible!